Vendor Intelligence Report: Eros Peptides

Executive summary

Across 3 Finnrick lab tests, Eros Peptides shows 2 pass / 1 fail — an overall pass rate of 67%. The record is unusually narrow: Finnrick has tested only Tirzepatide. That makes Eros a plausible but not preferred Tirzepatide source, especially because one failed sample prevents a repeat-clean read and the confidence picture changes materially under stricter methodology views. The data does not support extrapolating to Retatrutide, Semaglutide, Melanotan 2, bioregulators, or newer catalog additions.

Eros is not a no-documentation storefront. The canonical site publishes COAs, and the T 30MG page shows broader panels than purity alone. The weakness is traceability: some COA verification was blocked by Cloudflare, and a reviewed Janoshik Tirzepatide certificate listed Manufacturer and Batch as Unknown.

The non-lab intelligence is where the report gets sharper. Public records point to a Georgia retail operation with entity-name ambiguity across Eros Peptides LLC, Eros Industries LLC, and Eros Labs language, while the Terms of Service route disputes to Nevis and still contain a PeptideSciences.com artifact after that market exit. The GLP-1 catalog now uses single-letter labels — R, S, and T — in a regulatory environment where named GLP-1 product pages have drawn FDA action.

The highest-severity buyer-safety issue is authenticity and payment recourse. A live Eros-branded lookalike domain, erospeptidesusa.com, uses the logo and catalog style without the legal disclosures observed on the canonical site, and offers a crypto discount. Separately, a Trustpilot complaint alleges card-data theft after a processor change and an SSN request at checkout; the report treats that as unverified but material because Eros uses nonstandard payment rails.

Inside the full report:

• Appendix A Finnrick lab data and methodology-divergence charts for Tirzepatide
• Georgia entity, BBB, operator, and address reconciliation
• Terms of Service exhibit covering Nevis law and PeptideSciences artifact
• Domain comparison and clone-site evidence for erospeptidesusa.com
• COA chain-of-custody review, including blocked verification and unknown batch fields
• Payment-rail, Trustpilot, coupon-code, and regulatory-context analysis

Risk assessment

• Tirzepatide consistency risk — medium: Finnrick tested only Tirzepatide: 3 tests, 2 pass / 1 fail, current rating 77.95%, making Eros a plausible but not preferred Tirzepatide source.
• Legal-recourse and accountability risk — high: Terms select Nevis law, retain a PeptideSciences.com copy artifact, and public records point to virtual/mailbox addresses rather than a verified operating facility.
• Brand-confusion and copycat-purchase risk — high: erospeptidesusa.com clones Eros branding and catalog without visible legal disclosures; Eros does not provide sufficient public anti-counterfeit guidance.
• Payment-security and sensitive-data risk — high: A Trustpilot review alleges card-data theft after a processor change and an SSN request at checkout; checkout materials also show nonstandard payment rails.
• GLP-1 regulatory and product-identity risk — high: Retatrutide, Semaglutide, and Tirzepatide are now labeled R, S, and T, consistent with product-name obfuscation under active FDA GLP-1 enforcement pressure.
• COA and lot-traceability risk — medium: Eros publishes COAs, but some verification was blocked by Cloudflare and a reviewed Tirzepatide COA listed Manufacturer and Batch as Unknown.
• Undisclosed discount-code promotion risk — medium: Reddit HB15 code promotion and coupon-site code claims lacked clear disclosure, though no large X affiliate network was found.